Antipsychotic medication side effect assessment tools: A systematic review

Australian and New Zealand Journal of Psychiatry

Volumn 50, Issue 5, 2016, Pages 399-409

  Stomski, Norman Jay ^a   Morrison, Paul ^a   Meyer, Amanda ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

antipsychotic medication; assessment tool; side effect; Systematic review

Indexed keywords

NEUROLEPTIC AGENT;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ANTIPSYCHOTIC NON NEUROLOGICAL SIDE EFFECT RATING SCALE; APPROACH TO SCHIZOPHRENIA COMMUNICATION CLINIC; APPROACH TO SCHIZOPHRENIA COMMUNICATION SELF REPORT; ARIZONA SEXUAL EXPERIENCE SCALE; BARNES AKATHISIA SCALE; CONSTRUCT VALIDITY; CONTENT VALIDITY; DRUG SAFETY; EXTRAPYRAMIDAL SIDE EFFECT SCALE; EXTRAPYRAMIDAL SYMPTOM RATING SCALE; GLASGOW ANTIPSYCHOTIC SIDE EFFECT SCALE; HILLSIDE AKATHISIA SCALE; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; LIVERPOOL UNIVERSITY NEUROLEPTIC SIDE EFFECT RATING SCALE; MARYLAND PSYCHIATRIC RESEARCH CENTER SCALE; NURSING EXTRA PYRAMIDAL SYMPTOM ASSESSMENT SCALE; PRINCE HENRY HOSPITAL AKATHISIA RATING SCALE; PSYCHOMETRY; REVIEW; SIDE EFFECT ASSESSMENT; SYSTEMATIC MONITORING OF ADVERSE EVENT RELATED TO TREATMENT; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY; YALE EXTRAPYRAMIDAL SYMPTOM SCALE; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; STANDARDS;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 84964292252     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867415608244     Document Type: Review

References (65)

1. Aaronson N, Alonso J, Burnam A, et al. (2002) Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research 11: 193-205.
2. Ascher-Svanum H, Zhu B, Faries DE, et al. (2008) Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2: 67-77.
3. Barnes TR, (1989) A rating scale for drug-induced akathisia. The British Journal of Psychiatry 154: 672-676.
4. Barten JA, Pisters MF, Huisman PA, et al. (2012) Measurement properties of patient-specific instruments measuring physical function. Journal of Clinical Epidemiology 65: 590-601.
5. Bodfish JW, Newell KM, Sprague RL, et al. (1997) Akathisia in adults with mental retardation: Development of the Akathisia Ratings of Movement Scale (ARMS). American Journal of Mental Retardation 101: 413-423.
6. Byerly MJ, Nakonezny PA, Fisher R, et al. (2006) An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research 81: 311-316.
7. Cabeza IG, Amador MS, Lopez CA, et al. (2000) Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors. Schizophrenia Research 41: 349-355.
8. Cassady SL, Thaker GK, Summerfelt A, et al. (1997) The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Research 70: 21-37.
9. Chapman SC, Horne R, (2013) Medication nonadherence and psychiatry. Current Opinion in Psychiatry 26: 446-452.
10. Chouinard G, Ross-Chouinard A, Annable L, et al. (1980) Extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences 7: 233-239.
11. Dassori AM, Miller AL, Weiden PJ, (2003) The approaches to schizophrenia communication (ASC) tool: Including the patient perspective in treatment. Disease Management and Health Outcomes 11: 699-708.
12. Day JC, Wood G, Dewey M, et al. (1995) A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. The British Journal of Psychiatry 166: 650-653.
13. De Haan L, Weisfelt M, Dingemans PM, et al. (2002) Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 162: 24-28.
14. De Leeuw M, Van Meijel B, Grypdonck M, et al. (2012) The quality of the working alliance between chronic psychiatric patients and their case managers: Process and outcomes. Journal of Psychiatric and Mental Health Nursing 19: 1-7.
15. Dott SG, Weiden P, Hopwood P, et al. (2001) An innovative approach to clinical communication in schizophrenia: The approaches to schizophrenia communication checklists. CNS Spectrums 6: 333-338.
16. Evans R, Elwyn G, Edwards A, (2004) Review of instruments for peer assessment of physicians. British Medical Journal 328: 1240.
17. Fagan-Pryor EC, May DL, (2000) Establishment of interrater reliability for a nursing extrapyramidal side effects (EPS) assessment scale. Journal of Nursing Care Quality 14: 54.
18. Fleischhacker WW, Bergmann KJ, Perovich R, et al. (1989) The hillside akathisia scale: A new rating instrument for neuroleptic-induced akathisia. Psychopharmacology Bulletin 25: 222-226.
19. Gaebel W, Riesbeck M, Von Wilmsdorff M, et al. (2010) Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). European Neuropsychopharmacology 20: 310-316.
20. Gerlach J, Larsen EB, (1999) Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatrica Scandinavica-Supplementum 395, 113-117.
21. Gerlach J, Korsgaard S, Clemmesen P, et al. (1993) The St. Hans Rating Scale for extrapyramidal syndromes: Reliability and validity. Acta Psychiatrica Scandinavica 87: 244-252.
22. Goff DC, Hill M, Freudenreich O, (2010) Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry 71 (Suppl. 2): 20-26.
23. Guy E, (1976) Abnormal Involuntary Movement Scale. Rockville, MD: National Institute of Mental Health, U.S. Department of Health and Human Services.
24. Haddad PM, Brain C, Scott J, (2014a) Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Related Outcome Measure 5: 43-62.
25. Haddad PM, Fleischhacker WW, Peuskens J, et al. (2014b) SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology 4: 15-21.
26. Happell B, Manias E, Roper C, (2004) Wanting to be heard: Mental health consumers' experiences of information about medication. International Journal of Mental Health Nursing 13: 242-248.
27. Hellewell JSE, (1999) Do we know what matters to our patients. Clear perspectives: Manage issues. Schizophrenia Bulletin 2: 1-4.
28. Hogan TP, Awad AG, Eastwood R, (1983) A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychological Medicine 13: 177-183.
29. Hungerford C, Fox C, (2014) Consumer's perceptions of recovery-oriented mental health services: An Australian case-study analysis. Nursing and Health Sciences 16: 209-215.
30. Kalachnik JE, Sprague RL, (1993) The Dyskinesia Identification System Condensed User Scale (DISCUS): Reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations. Journal of Clinical Psychology 49: 177-189.
31. Kaneda Y, (2009) Assessing weight-related quality of life in persons with schizophrenia. International Medical Journal 16: 107-111.
32. Kikuchi T, Iwamoto K, Sasada K, et al. (2011) Reliability and validity of a new sexual function questionnaire (Nagoya Sexual Function Questionnaire) for schizophrenic patients taking antipsychotics. Human Psychopharmacology 26: 300-306.
33. Kim JH, Jung HY, Kang UG, et al. (2002) Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug-induced movement disorders. Movement Disorders 17: 1354-1359.
34. Lako IM, Bruggeman R, Liemburg EJ, et al. (2013) A brief version of the subjects' response to antipsychotics questionnaire to evaluate treatment effects. Schizophrenia Research 147: 175-180.
35. Leucht S, Komossa K, Rummel-Kluge C, et al. (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166: 152-163.
36. Lieberman JA, Stroup TS, McEvoy JP, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353: 1209-1223.
37. Lindstrom E, Jedenius E, Levander S, (2009) A symptom self-rating scale for schizophrenia (4S): Psychometric properties, reliability and validity. Nordic Journal of Psychiatry 63 (Suppl. 1-4): 368-374.
38. Lingjaerde O, Ahlfors UG, Bech P, et al. (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica-Supplementum 334, 1-100.
39. Llorca PM, (2008) Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Research 161: 235-247.
40. Loonen AJ, Doorschot CH, Van Hemert DA, et al. (2000) The schedule for the assessment of drug-induced movement disorders (SADIMoD): Test-retest reliability and concurrent validity. International Journal of Neuropsychopharmacology 3: 285-296.
41. Matson JL, Mayville EA, Bielecki J, et al. (1998) Reliability of the Matson Evaluation of Drug Side Effects Scale (MEDS). Research in Developmental Disabilities 19: 501-506.
42. Mazure CM, Cellar JS, Bowers MB Jr, et al. (1995) Assessment of extrapyramidal symptoms during acute neuroleptic treatment. Journal of Clinical Psychiatry 56: 94-100.
43. Mojtabai R, Corey-Lisle PK, Ip EH, et al. (2012) The patient assessment questionnaire: Initial validation of a measure of treatment effectiveness for patients with schizophrenia and schizoaffective disorder. Psychiatry Research 200: 857-866.
44. Mokkink Lidwine B, Terwee Caroline B, Patrick Donald L, et al. (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology 63: 737-745.
45. Morrison P, Meehan T, Stomski NJ, (2015a) Australian case managers' perceptions of mental health consumers use of antipsychotic medications and associated side-effects. International Journal of Mental Health Nursing 24: 104-111.
46. Morrison P, Meehan T, Stomski NJ, (2015b) Australian case managers' views about the impact of antipsychotic medication on mental health consumers. International Journal of Mental Health Nursing. Epub ahead of print 28. DOI: 10.1111/inm.12154.
47. Morrison P, Meehan T, Stomski NJ, (2015c) Living with antipsychotic medication side-effects: The experience of Australian mental health consumers. International Journal of Mental Health Nursing 24: 253-261.
48. Morrison P, Meehan T, Gaskill D, et al. (2000) Enhancing case managers' skills in the assessment and management of antipsychotic medication side-effects. Australian and New Zealand Journal of Psychiatry 34: 814-821.
49. Naber D, (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 10 (Suppl. 3): 133-138.
50. Naber D, (2008) Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiologia e Psichiatria Sociale 17: 174-176.
51. Naber D, Karow A, (2001) Good tolerability equals good results: The patient's perspective. European Neuropsychopharmacology 11 (Suppl. 4): S391-S396.
52. Nielsen RE, Lindstrom E, Nielsen J, et al. (2012) DAI-10 is as good as DAI-30 in schizophrenia. European Neuropsychopharmacology 22: 747-750.
53. Ohlsen RI, Williamson R, Yusufi B, et al. (2008) Interrater reliability of the antipsychotic non-neurological side-effects rating scale measured in patients treated with clozapine. Journal of Psychopharmacology 22: 323-329.
54. Prieto L, Sacristan JA, Gomez JC, (2004) The validity and reliability of the global index of safety (GIS). Current Medical Research and Opinion 20: 1825-1832.
55. Reeve BB, Wyrwich KW, Wu AW, et al. (2013) ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research 22: 1889-1905.
56. Roe D, Goldblatt H, (2009) Why and how people decide to stop taking prescribed psychiatric medication: Exploring the subjective process of choice. Psychiatric Rehabilitation Journal 33: 38-46.
57. Sachdev P, (1994) A rating scale for acute drug-induced akathisia: Development, reliability, and validity. Biological Psychiatry 35: 263-271.
58. Salomon C, Hamilton B, (2013) 'All roads lead to medication?' Qualitative responses from an Australian first-person survey of antipsychotic discontinuation. Psychiatric Rehabilitation Journal 36: 160-165.
59. Seale C, Chaplin R, Lelliott P, et al. (2007) Antipsychotic medication, sedation and mental clouding: An observational study of psychiatric consultations. Social Science & Medicine 65: 698-711.
60. Simpson GM, Angus JW, (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica-Supplementum 212: 11-19.
61. Stomski NJ, Mackintosh S, Stanley M, (2010) Patient self-report measures of chronic pain consultation measures: A systematic review. The Clinical Journal of Pain 26: 235-243.
62. Terwee CB, Bot SD, De Boer MR, et al. (2007) Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology 60: 34-42.
63. Waddell L, Taylor M, (2008) A new self-rating scale for detecting atypical or second-generation antipsychotic side effects. Journal of Psychopharmacology 22: 238-243.
64. Wolters HA, Knegtering R, Wiersma D, et al. (2006) Evaluation of the subjects' response to antipsychotics questionnaire. International Clinical Psychopharmacology 21: 63-69.
65. Yen CF, Lee Y, Tang TC, et al. (2009) Predictive value of self-stigma, insight, and perceived adverse effects of medication for the clinical outcomes in patients with depressive disorders. Journal of Nervous and Mental Disease 197: 172-177.